Abstract | PURPOSE: MATERIALS AND METHODS: RESULTS: CONCLUSIONS:
Metformin use in veterans with prostate cancer who receive androgen deprivation therapy is associated with improved oncologic outcomes. This association should be evaluated in a prospective clinical trial.
|
Authors | Kyle A Richards, Jinn-Ing Liou, Vincent L Cryns, Tracy M Downs, E Jason Abel, David F Jarrard |
Journal | The Journal of urology
(J Urol)
Vol. 200
Issue 6
Pg. 1256-1263
(12 2018)
ISSN: 1527-3792 [Electronic] United States |
PMID | 29940252
(Publication Type: Journal Article)
|
Copyright | Copyright © 2018 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved. |
Chemical References |
- Androgen Antagonists
- Hypoglycemic Agents
- Metformin
|
Topics |
- Aged
- Androgen Antagonists
(therapeutic use)
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Cancer Survivors
(statistics & numerical data)
- Databases, Factual
(statistics & numerical data)
- Diabetes Mellitus, Type 2
(drug therapy, mortality)
- Humans
- Hypoglycemic Agents
(therapeutic use)
- Male
- Metformin
(therapeutic use)
- Neoplasm Staging
- Prospective Studies
- Prostatic Neoplasms
(drug therapy, mortality, pathology)
- Retrospective Studies
- Survival Analysis
- Treatment Outcome
- United States
(epidemiology)
- United States Department of Veterans Affairs
- Veterans
(statistics & numerical data)
|